US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Expanded Access Program for Magrolimab
Sponsor: Gilead Sciences
This observational or N/A phase trial investigates Relapsed/Refractory Acute Myeloid Leukemia and is currently ongoing. Gilead Sciences leads this study, which shows 12 recorded versions since 2026 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
No Longer Available
-
Jul 2024 — Sep 2024 [monthly]
No Longer Available
-
Mar 2024 — Jul 2024 [monthly]
No Longer Available
Status: Temporarily Not Available → No Longer Available
-
Feb 2024 — Mar 2024 [monthly]
Temporarily Not Available
-
Dec 2023 — Feb 2024 [monthly]
Temporarily Not Available
▶ Show 7 earlier versions
-
Oct 2023 — Dec 2023 [monthly]
Temporarily Not Available
Status: Available → Temporarily Not Available
-
Jun 2023 — Oct 2023 [monthly]
Available
-
May 2023 — Jun 2023 [monthly]
Available
-
Mar 2023 — May 2023 [monthly]
Available
-
Feb 2023 — Mar 2023 [monthly]
Available
-
Jan 2023 — Feb 2023 [monthly]
Available
-
Dec 2022 — Jan 2023 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.